Regulatory Updates, Senior Level Appointments, Earnings Releases, Facilities Closures and New Plants - Analyst Notes on Teva, Medtronic, Regeneron, NextEra Energy and Duke Energy - KNOE 8 News; KNOE-TV; KNOE.com |

Regulatory Updates, Senior Level Appointments, Earnings Releases, Facilities Closures and New Plants - Analyst Notes on Teva, Medtronic, Regeneron, NextEra Energy and Duke Energy

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Analysts Review

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, May 16, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Limited (NYSE: TEVA), Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), NextEra Energy, Inc. (NYSE: NEE) and Duke Energy Corporation (NYSE: DUK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2563-100free.

Teva Pharmaceutical Industries Limited Analyst Notes

On May 13, 2014, Teva Pharmaceuticals Industries Ltd. (Teva) announced the U.S. Food and Drug Administration's (FDA) acceptance of the Company's supplemental new drug application (sNDA) filing for pediatric indication for QNASL Nasal Aerosol. Teva informed that QNASL is a waterless intranasal corticosteroid spray presently used for treating nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients aged 12 years and above. Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development, said, "We are very pleased the FDA has accepted for review the sNDA for QNASL®. If the FDA approves the new indication for QNASL®, it will become the first waterless HFA nasal allergy treatment approved for patients as young as 4 years of age. The low-dose formulation demonstrates our commitment to the development of innovative treatment options for all patients with respiratory conditions, including nasal allergies." The full analyst notes on Teva are available to download free of charge at:

http://www.analystsreview.com/2563-TEVA-16May2014.pdf

Medtronic, Inc. Analyst Notes

On May 13, 2014, Medtronic, Inc. (Medtronic) announced the appointment of Hooman Hakami as Executive Vice President and Group President of the Medtronic Diabetes Group. According to Medtronic, in this role Hakami will head Medtronic's entire global diabetes franchise, including research and development, operations, and sales and marketing. In a separate announcement on the same day, the Company informed that it will report its financial results for Q4 FY 2014 on Tuesday, May 20, 2014 at around 6:15 a.m. CDT. As per data from Zacks Investment Research, the consensus EPS estimate for Q4 FY 2014 is $1.12. The full analyst notes on Medtronic are available to download free of charge at:

http://www.analystsreview.com/2563-MDT-16May2014.pdf

Regeneron Pharmaceuticals, Inc. Analyst Notes

On May 8, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced financial results for Q1 2014. Regeneron's revenues during the quarter increased 42.3% YoY to $625.7 million, beating Reuters' analysts' estimates of $609.5 million. Regeneron stated that Q1 2014 revenues include collaboration revenues of $256 million, which increased from $114 million in Q1 2013, mainly due to an increase in the Company's net profit from commercialization of EYLEA outside the United States and higher reimbursement of antibody development costs by Sanofi. The Company's net income during the quarter declined to $65.4 million, or $0.58 per diluted share, from $98.9 million, or $0.90 per diluted share, in Q1 2013. On an adjusted basis, the Company's net income increased to $2.26 per diluted share from $1.78 per diluted share in Q1 2013. On average, analysts polled by Reuters expected the Company to report an adjusted diluted EPS of $0.94 in Q1 2014. The full analyst notes on Regeneron are available to download free of charge at:

http://www.analystsreview.com/2563-REGN-16May2014.pdf

NextEra Energy, Inc. Analyst Notes

On May 12, 2014, Platts, a division of McGraw Hill Financial, reported that NextEra Energy Resources, a subsidiary of NextEra Energy Inc., is planning to shut two of its wind farms in Texas in August 2014, as both were extensively destructed by ice storms in November 2013. According to the report, the Company has notified the Electric Reliability Council of Texas about its plan to shut the two facilities which have a combined capacity of 78 MW. The report quoted the Company's spokesperson Steve Stengel as saying "We made this decision for economic reasons. Estimates to fix the damage exceeded the economic value of the projects. Therefore, we made the decision to cease operations." The full analyst notes on NextEra Energy are available to download free of charge at:

http://www.analystsreview.com/2563-NEE-16May2014.pdf

Duke Energy Corporation Analyst Notes

On May 13, 2014, Duke Energy Corporation (Duke Energy) announced plans to build three new major power plants in Florida, aimed at meeting its customers' rising energy needs. According to the plan, if approved by the Florida Public Service Commission, the Company will construct a combined-cycle natural gas plant in Citrus County and two simple-cycle combustion turbine generators at the Suwannee Plant near Live Oak. Additionally, it will install new equipment at the Hines Energy Complex near Bartow to increase efficiency and power output. Alex Glenn, Duke Energy State President - Florida, said, "We are making these investments to continue providing our customers with the most cost-effective energy solutions and highest level of reliability with limited environmental impact. We are committed to ensuring our customers' energy needs are met 24 hours a day, seven days a week now and in the future." The full analyst notes on Duke Energy are available to download free of charge at:

http://www.analystsreview.com/2563-DUK-16May2014.pdf

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://wwww.AnalystsReview.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KNOE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.